Ixekizumab effective in psoriatic arthritis up to 1 year regardless of methotrexate use
Ixekizumab is efficacious in patients with psoriatic arthritis for up to 1 year, with or without concomitant methotrexate use, according to data published in Arthritis Research & Therapy.“Ixekizumab has been demonstrated to improve the signs and symptoms of PsA in patients who were biologic-naive (SPIRIT-P1) or had previous inadequate response or intolerance with TNF inhibitors